[Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
We have periodically monitored CA125 in 21 primary ovarian cancer patients who were clinically diagnosed as in the remission state after cytoreductive surgery and a combination chemotherapy 200 days after surgery. In this monitoring, the mean attenuating curve (exponential curve) of CA125 within 75 days after surgery was obtained, Y = 2.4831 exp (-0.11281 x 10-1X) [Y:log10 (CA125), X:days from the surgery]. According to this formula, the half life of CA125 is 11.5 days and CA125 is supposed to decrease to under 35U/ml in 42.1 days. In the patients whose preoperative CA125 was over 1,000U/ml (n = 8), the half life was 6.8 days and CA125 fell below 35U/ml within 45.8 days. In the rest of the patients, (35U/ml less than preoperative CA125 less than 1,000U/ml), these figures were 16.3 days and 38.2 days, respectively. Then in the patients whose tumors were completely resected (n = 13), the mean attenuating curve was Y = 2.3655 exp (-0.99935 x 10(-2)X), the half life was 13.6 days, and CA125 decreased to under 35U/ml in 42.7 days. After primary surgery, CA125 decreased to 50.0 +/- 54.2% of the preoperative concentration. Among 16 patients (without 5 P-MFC chemotherapy) 13 (13/16, 81.3%) showed CA125 under 35U/ml after 2 courses of chemotherapy. Thus, it became clear that CA125 decreases in the remission state of ovarian cancer.
Kawai
M
M
Department of Obstetrics and Gynecology, Toyohashi City Hospital, Aichi.
Inagaki
S
S
Yamashita
H
H
Imaizumi
H
H
Kakihara
M
M
Arii
Y
Y
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006207:Half-Life; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D010440:Peptichemio / Q000008:administration & dosage; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D008937:Mitomycins; D003561:Cytarabine; D001761:Bleomycin; D003609:Dactinomycin; D016685:Mitomycin; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio; D002945:Cisplatin; D005472:Fluorouracil